Company profile
OrganoTherapeutics company profile
OrganoTherapeutics use cutting-edge human-specific mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease. We screen new molecules on our proprietary human-specific minibrains which represent a model mimicking faithfully the human Parkinson’s disease pathology. OrganoTherapeutics aims at developing new drug candidates against Parkinson’s disease which are tested in state-of-the art 3D patient models. OrganoTherapeutics has developed first own proprietary drug candidates and has access to attractive libraries for further screening.
Business identity
- Contact email
- [email protected]
- Phone number
- +4917680774615
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 1-10 employees
- Revenue range
- $0+
- Founded
- 2019-01-01, Year
Headquarters
- Headquarters
- Qarqaraly, Karaganda, Kazakhstan
- Postal code
- L-4365
- Country code
- KZ
- Continent
- Asia